iRhythm Surges 17.68% on $310M Top 500 Volume Powered by Q2 Earnings and AI Partnership

iRhythm Technologies (IRTC) surged 17.68% on August 1, 2025, with a trading volume of $310 million, marking a 155.72% increase from the prior day. The stock’s performance followed the company’s Q2 2025 earnings report, which highlighted a 26.1% year-over-year revenue rise to $186.7 million and a 71.2% gross margin, up 130 basis points. Operational momentum was driven by core long-term monitoring, Zio AT adoption, and international expansion, including eight new commercial accounts in Japan. The firm also announced a strategic partnership with Lucem Health to leverage AI for early arrhythmia detection, aligning with its predictive care vision.

Financial guidance was raised for 2025, with revenue projected between $720–730 million and adjusted EBITDA margin of 8.0–8.5%. CFO Daniel Wilson noted incremental remediation costs and tariff impacts but emphasized operational efficiencies and expanded market access, including 10 million additional patients. International growth remains a focus, with steady progress in the U.K., Europe, and Japan. The company’s unrestricted cash balance stood at $545.5 million, supporting its innovation pipeline and regulatory compliance efforts.

A backtest of a strategy purchasing top 500 volume stocks and holding for one day generated a 166.71% return from 2022 to the present, outperforming the benchmark by 137.53%. This underscores the potential of high-liquidity strategies in capturing short-term market shifts, particularly in sectors with strong earnings momentum like iRhythm’s digital health niche.